Deligoparin sodium

Drug Profile

Deligoparin sodium

Alternative Names: OP 2000

Latest Information Update: 20 Sep 2002

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Opocrin
  • Class Anti-inflammatories; Anticoagulants; Antithrombotics; Low molecular weight heparins
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Ulcerative colitis; Unstable angina pectoris

Most Recent Events

  • 17 Sep 2002 Discontinued - Phase-III for Ulcerative colitis in USA (SC)
  • 29 Aug 2002 Incara has completed patient enrolment in its phase II/III trial of deligoparin for the treatment of ulcerative colitis
  • 20 Mar 2002 A study has been added to the Inflammatory Bowel Disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top